sabizabulin
-
Valeo Pharma Impresses Again with 210% Quarterly Year-over-Year Revenue Growth
Valeo Pharma Inc. (TSX: VPH | OTCQB: VPHIF) (“Valeo”) just released their FQ1/2023 earnings results and impressed again.…
-
Steve Saviuk, CEO of Valeo Pharma, Discusses Promising Results of COVID-19 Drug Sabizabulin and Revenue Growth in 2023
In this InvestorIntel interview, Tracy Weslosky talks to Valeo Pharma Inc.’s (TSX: VPH | OTCQB: VPHIF) Founder, CEO, and…
-
Record revenues in 2022 of $27.7 million, Valeo Pharma investment in commercial infrastructure starts to pay off
What a difference a year makes. Last year at this time we were heading into wave something or…
-
Steve Saviuk on how Valeo Pharma’s ‘life changing’ products have delivered the strong growth forecasted for 2022
In this InvestorIntel interview, Tracy Weslosky interviews Valeo Pharma Inc.’s (TSX: VPH | OTCQB: VPHIF) Founder, CEO and…
-
Valeo Pharma keeps delivering with a 100% revenue growth forecast in 2022 and more new effective pharmaceuticals
Early in 2022 InvestorIntel updated readers about a company that was growing its revenue at an incredible rate…